Phase three clinical trial of herbal medicine Vipdervir to treat COVID-19
According to the clinical trial schedule approved by Ministry of Health, on November 22, Vipdervir was transferred to National Hospital for Tropical Diseases to conduct a phase three clinical trial on 200 COVID-19 patients.
In order to participate in the trial, patients must meet many criteria such as not being too severe with COVID-19, not having some underlying diseases, not currently using some specific medicines. Assoc. Prof. Dr. Huan shared that it is still unknown how long the trial will last because the selection of volunteers is quite complicated and difficult, only serious patients are taken to National Hospital for Tropical Diseases, while severe patients are not eligible to participate in the trials.
Assoc. Prof. Dr. Le Quang Huan at the seminar on the morning of November 23
Assoc. Prof. Dr. Huan said that during the trial, the research team determined the optimal dose for patients after phase two ended. The third phase of trial will not be divided into groups of patients taking different doses, but using the same dose. After the third phase clinical trial, he hopes to have official results in the next two months to be recognized as a circulated medicine.
Previously, on August 10, 2021, Vietnam Academy of Science and Technology held an online press conference to announce the results of preclinical research on COVID-19 medicine. Vipdervir is a safe and effective medicine that inhibits the growth of the SARS-CoV-2 virus and helps strengthen the patient's immune system. Vipdervir has been evaluated for acute toxicity at Central Institute for Drug Control and Hanoi Medical University, and evaluated for its ability to inhibit influenza A/H5N1 virus at Institute of Biotechnology, to inhibit SARS-CoV-2 virus at National Institute of Hygiene and Epidemiology, and the ability to increase immunity at Hanoi Medical University.
Translated by Phuong Ha
Link to Vietnamese version